Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb 28;8(1):3828.
doi: 10.1038/s41598-018-21644-y.

The Spanish version of Face-Name Associative Memory Exam (S-FNAME) performance is related to amyloid burden in Subjective Cognitive Decline

Collaborators, Affiliations

The Spanish version of Face-Name Associative Memory Exam (S-FNAME) performance is related to amyloid burden in Subjective Cognitive Decline

Angela Sanabria et al. Sci Rep. .

Abstract

The Face-Name Associative Memory Exam (FNAME) is a paired associative memory test created to detect memory deficits in individuals with preclinical Alzheimer's disease (AD). Worse performance on FNAME in cognitively healthy individuals were found related to higher amyloid beta (Aβ) burden measured with Positron-Emission-Tomography using 11C-PiB (PiB-PET). We previously reported normative data of a Spanish version of FNAME (S-FNAME) in cognitively healthy Spanish-speaking subjects. The aim of the present study was to determine whether performance on S-FNAME was associated with Aβ burden in subjective cognitive decline (SCD) individuals. 200 SCD subjects received neurological and neuropsychological assessments, including the S-FNAME and the Word List task from the Wechsler-Memory-Scale-III (WMS-III). Moreover, they received an MRI and (18)F-Florbetaben Positron-Emission-Tomography (FBB-PET) to measure Aβ burden. Three cognitive factor composites were derived for the episodic memory measures (face-name [SFN-N], face-occupation [SFN-O] and WMS-III) to determine whether episodic memory performance was related to Aβ deposition. Higher global Aβ deposition was significantly related to worse performance on SFN-N but not with SFN-O or WMS-III Composite. Moreover, worse SFN-N performance was significantly related to higher Aβ deposition in bilateral Posterior Cingulate Cortex. The S-FNAME may be a promising neuropsychological tool for detecting SCD individuals with preclinical AD.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interests, except for Mercè Boada who has consulted for Araclon, Avid, Grifols, Lilly, Nutricia, Roche and Servier. She received fees for lectures and funds for research from Araclon, Grifols, Nutricia, Roche and Servier. She has not received personal compensations from these organizations.

Figures

Figure 1
Figure 1
Plotting Global Amyloid against SFN-N and Global FBB-PET SUVR.
Figure 2
Figure 2
Logistic Regression revealed a significant relationship between FBB-PET positive classification and lower performance on the SFN-N Composite. A t-test comparison showed that the FBB-PET positive group performed significantly worse than the FBB-PET negative group on the SFN-N Composite.

References

    1. Blennow K, Leon MJde, Zetterberg H. Alzheimer’s Disease. Lancet. 2006;368:387–403. doi: 10.1016/S0140-6736(06)69113-7. - DOI - PubMed
    1. World Health Organization. Dementia: a public health priority. (2012).
    1. Jessen F, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimer’s Dement. 2014;10:844–852. doi: 10.1016/j.jalz.2014.01.001. - DOI - PMC - PubMed
    1. Mitchell AJ, Beaumont H, Ferguson D, Yadegarfar M, Stubbs B. Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: Meta-analysis. Acta Psychiatr. Scand. 2014;130:439–451. doi: 10.1111/acps.12336. - DOI - PubMed
    1. Geerlings, M. I., Jonker, C., Bouter, L. M., Adèr, H. J. & Schmand, B. Association between memory complaints and incident Alzheimer’s disease in elderly people with normal baseline cognition. Am. J. Psychiatry156, 531–537 (1999). - PubMed

Publication types

Substances